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Quantum dots (QDs) are attractive photoluminescence probes for biomedical imaging due to their
unique photophysical properties. However, the potential toxicity of QDs has remained a major obstacle to
their clinical use because they commonly incorporate the toxic heavy metal cadmium within the core of
the QDs. In this work, we have evaluated a novel type of heavy metal-free/cadmium-free and biocom-
patible QD nanoparticles (bio CFQD® nanoparticles) with a good photoluminescence quantum yield.
Sentinel lymph node mapping is an increasingly important treatment option in the management of
breast cancer. We have demonstrated their potential for lymph node mapping by ex vivo imaging of
regional lymph nodes after subcutaneous injection in the paw of rats. Using photoluminescence imaging
and chemical extraction measurements based on elemental analysis by inductively coupled plasma mass
spectroscopy, the quantum dots are shown to accumulate quickly and selectively in the axillary and
thoracic regional lymph nodes. In addition, lifetime imaging microscopy of the QD photoluminescence
indicates minimal perturbation to their photoluminescence properties in biological systems.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Many cancers metastasise via the lymphatic system, therefore
the presence of lymph node metastasis is an important prognostic
marker in many cancers including melanoma, breast, colon, lung
and ovarian cancers [1,2]. Breast cancer cells are most likely to
spread to the lymph nodes (LNs) located in the axilla, therefore
accurate assessment of the axillary lymph nodes (ALN) is the most
prognostic indicator of survival and recurrence in patients withlymph node; ALND, Axillary
biopsy; SLN, sentinel lymph
, near-infra red; QD, quantum
, reticuloendothelial system;
, transmission electron mi-
cic lymph node; LED, light-
eft thoracic lymph node; ICP-
FLIM, ﬂuorescence lifetime
acid; TMS, trimethylsilyl; HF,
i).
r Ltd. This is an open access article(early-stage) breast cancer. Axillary lymph node dissection (ALND)
has long been used for the management of the breast cancer.
However, ALND is associated with considerable short and long-
term morbidities such as seroma formation, impairment of shoul-
der motion, numbness, paresthesias, nerve injury, wound infection,
and arm lymphoedema. In addition patients must stay in hospital
for longer with signiﬁcant cost implications. Moreover, most pa-
tients with early-stage breast cancer are node negative, and ALND
exposes them to the potential side effects of this procedure with no
beneﬁt [3e5].
These complications have led to the concept of sentinel lymph
node biopsy (SLNB) as a minimally invasive procedure used for
stagingmelanoma and breast cancer and its use is being studied for
other types of solid cancers [6e8]. A sentinel lymph node (SLN) is
deﬁned as the ﬁrst lymph node(s) to receive lymphatic drainage
from the site of a tumour. With this method, SLN can be identiﬁed
using tracer agents (e.g radiolabelled colloid, and or vital blue dye)
which are injected around the primary tumour site. After a few
minutes the axilla is minimally incised, and stained lymphatic
vessels and stained lymph nodes are detected visually. The com-
bination of radioactive lymphatic tracers and blue dye stainingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Although blue dyes are straightforward, inexpensive and safe to
use, their efﬁciency in identifying SLNs is limited. Blue dye mole-
cules (e.g., Patent Blue V, Evans blue, methylene blue) are too small
and migrate quickly from the SLN to the entire lymphatic system.
As a result, the prolonged preparation time increases blue staining
of secondary, third and sequential nodes. Therefore, surgical skill
and experience are required to locate and remove the SLNs before
the dye spreads to other nodes. The dyes have also been reported to
cause various allergic reactions in patients such as rush, erythaema
and anaphylactic reaction [14,15]. With the radioactive tracing
approach, speciﬁc techniques, equipment (Gamma camera) and
training are needed to minimise the hazard to patients and staff.
Close collaboration with a licensed nuclear medicine facility is
required, incurring logistical and waste disposal problems [16,17].
The use of iron oxide nanoparticles (NPs) detected with a hand-
held magnetometer probe is another approach which has been
used to identify the SLN [18e21]. With this approach, the SLN can
be identiﬁed using the point-source magnetometer probe but im-
aging requires MRI scanning. Moreover, the surgeon cannot use
metallic surgical instruments with these techniques.
Fluorescent agents administered locally or systemically are used
extensively for preclinical in vivo imaging and increasingly for
image-guided surgery in human patients. Fluorescent organic
molecules and nanoparticles offer an alternative approach to con-
ventional lymphotropic agents of the SLN mapping, to enable
transcutaneous real-time lymphography and intraoperative lymph
node detection. One of the currently approved ﬂuorescent contrast
agents by the FDA for clinical applications is indocyanine green
(ICG), which has been widely used in clinical research due to its
near-infra red (NIR) ﬂuorescent emission which entails low auto-
ﬂuorescence and increased tissue transparency [22,23]. The use of
ICG for the visualisation of the lymphatic mapping was ﬁrst
described byMotomura et al., in 1999 [24]. ICG has been used as the
lymphatic tracer for SLN mapping in breast cancer, gastric cancer,
and colon cancer. However, as with the blue dyes, ICG is rapidly
cleared through the sentinel node to second-tier nodes eventually
spreading to the subcutaneous tissue, and its relatively low ﬂuo-
rescence quantum yield (QY) and rapid photobleaching limit ICG's
usefulness for intraoperative SLN mapping [25].
Semiconductor quantum dot (QD) nanoparticles have attracted
much attention over the past few years as a novel class of lumi-
nescence probes for many biological and biomedical applications
[26e29]. The main advantages for the use of QDs as bioimaging
probes are their photophysical properties such as high photo-
luminescence (PL) quantum yield, high photobleaching threshold,
size and composition-dependent tunable photoluminescence that
can span the entire spectrum and high photostability compared to
organic dyes [30,31]. They have therefore become promising al-
ternatives to organic ﬂuorophores in many applications particularly
as probes for biomedical imaging [32].
One of the ﬁrst uses of QDs in vivo was mapping the reticulo-
endothelial system (RES) and locating draining lymph nodes
[33,34]. Ballou et al. were amongst the ﬁrst to inject the QDs into
the tumours to map SLNs [33]. They demonstrated that tumour
injection of QDs resulted in rapidmigration of QDs from the tumour
through lymphatics to surrounding lymph nodes which were
visible through the skin. Frangioni and colleagues used NIR emit-
ting CdTe/CdSe core/shell QDs and demonstrated SLN mapping of
QDs when injected intradermally into the paw of a mouse [34].
They also injected NIR QDs intradermally on the thighs of pigs and
followed lymphatic ﬂow towards the SLN in real time [34]. Since
the ﬁrst examples from Ballou's and Frangioni's groups a signiﬁcant
amount of effort has been applied to investigate the potential of
QDs as luminescence probes for SLN mapping [35e41]. Preliminarydata and studies suggest that SLN detection guided by QD nano-
particles could emerge as a new method for SLN mapping. How-
ever, one major drawback that severely hinders the clinical
translation of QDs is the inherent toxicity of the individual ions
(such as Cd2þ, Se2 and Te2) that the dots contain, particularly
Cd2þ [42e44]. For instance in study by Marchal et al. the detection
of the SLN and the toxicity of the cadmium-containing QDs
(CdTeSe/CdZnS) were compared with cadmium-free counterparts
(CuInS2/ZnS) [45]. They also noted that the cadmium-based QDs
clearly showed signs of toxicity, with inﬂammation evident in
resected regional lymph nodes. However, the cadmium-free QDs
did not show any signs of toxicity under the same conditions.
Therefore, in recent years several groups have been interested in
the fabrication of cadmium-free QDs for biological applications
[46e48].
QDs made up of IIIeV semiconductor nanocrystals (such as InP)
are appropriate candidates as they do not have class A or B ele-
ments and also structurally are more robust owing to the presence
of covalent bonds in their matrix [49,50]. Indium-based QDs are
therefore a promising substitute for cadmium-based QDs for bio-
logical studies. Several other core-shell combinations including
indium for Cadmium-free QDs have been investigated successfully
for in vivo imaging [51,52].
Nevertheless, relatively few studies have reported the use of
indium-based QDs in biomedical applications, since the synthetic
procedure for preparing indium-based QDs is more complicated
than cadmium-based QDs. The aim of our study was to demon-
strate the applicability and effectiveness of new biocompatible
water soluble indium-based QDs (bio CFQD® nanoparticles, Nanoco
Technologies Ltd.) and investigate their applicability for in vivo
axillary lymphatic mapping.
2. Materials and methods
2.1. Synthesis of bio CFQD® nanoparticles
Bio CFQD® nanoparticles based on indium (In) compositions
weremanufactured in the laboratories of Nanoco Technologies Ltd.,
Manchester, UK using proprietary synthetic procedures following
the patented molecular seeding process [53].
Brieﬂy, the preparation of crude (non functionalised) indium-
based quantum dots with emission in the range of 500e700 nm
was carried out as follows: Dibutyl ester (approximately 100 mL)
and myristic acid (MA) (10.06 g) were placed in a three-neck ﬂask
and degassed at ~70 C under vacuum for 1 h. After this period,
nitrogen was introduced and the temperature was increased to
~90 C. Approximately 4.7 g of the ZnS molecular cluster [Et3NH4]
[Zn10S4(SPh)l6] was added, and the mixture was stirred for
approximately 45 min. The temperature was then increased to
~100 C, followed by the drop-wise additions of In (MA)3 (1 M,
15 mL) followed by (TMS)3P (1 M, 15 mL). The reaction mixture was
stirred while the temperature was increased to ~140 C. At 140 C,
further drop-wise additions of In (MA)3 dissolved in di-n-butylse-
bacate ester (1 M, 35 mL) (left to stir for 5 min) and (TMS)3P dis-
solved in di-n-butylsebacate ester (1 M, 35 mL) were made. The
temperature was then slowly increased to 180 C, and further drop-
wise additions of In (MA)3 (1 M, 55 mL) followed by (TMS)3P (1 M,
40 mL) were made. By addition of the precursor in this manner,
indium-based particles with an emission maximum gradually
increasing from 500 nm to 720 nm were formed. The reaction was
stopped when the desired emission maximum was obtained and
left to stir at the reaction temperature for half an hour. After this
period, the mixture was left to anneal for up to approximately 4
days (at a temperature ~20e40 C below that of the reaction). A UV
lamp was also used at this stage to aid in annealing. The particles
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(approximately 200 mL) via cannula techniques. The precipitate
was allowed to settle and then methanol was removed via cannula
with the aid of a ﬁlter stick. Dried degassed chloroform (approxi-
mately 10mL) was added towash the solid. The solid was left to dry
under vacuum for 1 day. This procedure resulted in the formation of
indium-based nanoparticles on ZnS molecular clusters. In post-
operative treatments, the quantum yields of the resulting indium-
based nanoparticles were further increased by washing in dilute
hydroﬂuoric acid (HF). The quantum efﬁciencies of the indium-
based core material ranged from approximately 25%e50%.
Growth of a ZnS shell: A 20mL portion of the HF-etched indium-
based core particles was dried in a three-neck ﬂask. 1.3 g of myristic
acid and 20 mL di-n-butyl sebacate ester were added and degassed
for 30 min. The solution was heated to 200 C, and 2 mL of 1 M
(TMS)2S was added drop-wise (at a rate of 7.93 mL/h). After this
additionwas complete, the solutionwas left to stand for 2 min, and
then 1.2 g of anhydrous zinc acetate was added. The solution was
kept at 200 C for 1 h and then cooled to room temperature. The
particles were isolated by adding 40 mL of anhydrous degassed
methanol and centrifuging. The supernatant liquid was discarded,
and 30 mL of anhydrous degassed hexane was added to the
remaining solid. The solutionwas allowed to settle for 5 h and then
centrifuged again. The supernatant liquid was collected and the
remaining solid was discarded. The quantum efﬁciencies of the
ﬁnal unfunctionalised (crude) indium-based nanoparticle material
ranged from approximately 60%e90% in organic solvents.
Water solubilisation and surface functionalisation of the crude
nanoparticles was achieved using a proprietary method based on
surface crosslinking with hexamethoxymethylmelamine (HMMM)
[54]. The details of this method of functionalisation will be
described in a separate publication. Brieﬂy, a toluene solution of
crude nanoparticles was reﬂuxed under nitrogen in the presence of
amphiphilic ligands and polyethylene glycol (PEG). Following
several hours of reﬂux, the toluene was removed by evaporation
and then the product was reconstituted in deionised H2O. The
aqueous solution of dots was puriﬁed by several cycles of ultraﬁl-
tration using 30kD centrifugation ultraﬁlters. The dots were grafted
with PEG to increase solubility of the nanoparticles and to prolong
their blood-half-life by reducing their reticuloendothelial system
(RES) uptake [55,56]. The water soluble surface treated nano-
particles (bio CFQD®) displayed relatively high photoluminescence
quantum yields (0.35e0.45) in aqueous buffers (pH 5e8) and were
stable for at least several months in water with negligible PL loss or
precipitation.
2.2. Characterisation of bio CFQD® nanoparticles
Transmission electron microscopy (TEM) analysis was chal-
lenging due to the low electron density nature of the particles. Fig.1
(A and B) shows a typical TEM image and the size distribution of a
typical sample of the bio CFQD® nanoparticles. The TEM images
were acquired using a JEOL 2010 analytical TEM. The hydrodynamic
particle size was determined by the measurement of dynamic light
scattering (DLS) using a Malvern Zetasizer mV system. The nano-
particles were dispersed in aqueous buffer (HEPES 6 mM, pH 7.8).
The average hydrodynamic size of the surface-treatedwater soluble
particles (bio CFQD®) is 12.2 nm with a standard deviation of
0.29 nm (Fig. 1C).
Fig. 1D shows the photoluminescence emission spectrum of the
bio CFQD® nanoparticles in distilled water, which shows peak
emission at 615 nm. The photoluminescence emission spectrum of
QDs was recorded using a ﬁbre optic CCD spectrometer (USB4000,
Ocean Optics Inc.). For the quantum yield measurement a spec-
trometer incorporating an integrating sphere was used(Hamamatsu UK. Ltd, model C9920-02), which has been speciﬁcally
designed to measure absolute quantum yields.
2.3. Cell culture
MCF-7 cell line (human breast adenocarcinoma) was obtained
from Sigma-Aldrich. The cells were grown in DMEM-F12 medium
containing 10% FCS. All culture ﬂasks were kept inside a humidiﬁed
incubator at 37 C and 5% CO2.
2.4. In vitro toxicity test
The effect of bio CFQD® nanoparticles on viability of MCF-7 cells
was evaluated with the use of the MTT viability assay. Brieﬂy, cells
were seeded on each well of 96-well-plate at a density of 5 103 and
cultured in a humidiﬁed 5% CO2 incubator at 37 C for 24 h. The next
day, the culture medium was removed and was replaced with fresh
cell culture medium containing various concentrations of QDs
(12.5e200 nM). Cells without QDs were used as the control. Cell
viability was measured after 24 and 48 h incubation using the MTT
assay. Experimentswere carriedout in triplicate. Following incubation
with the QDs, the culture medium was removed and 100 mL of MTT
(1mg/mL)wasadded into eachwell and incubatedat 37 C for2h. The
water-insoluble formazan crystals were solubilised with dimethyl
sulfoxide (DMSO) and the optical density (OD) of eachwell at 565 nm
was recorded on a microplate reader (BioTek Instruments Inc.)
2.5. Animal experiments
150e175 g female Hooded Lister rats were purchased from
Harlan UK Ltd and acclimatised to the animal facility for 7 days
prior to experimentation. Animals were kept in 12 h light/dark
cycles and had free access to food and water. All procedures were
carried out with Home Ofﬁce licence approval.
2.6. Haemolysis test
Fresh red blood cells (RBC) obtained from rats were suspended
in physiological saline (0.9% sodium chloride) (negative control),
deionised water (positive control) or various bio CFQD® nano-
particles dilutions in sodium chloride, ranging from 12.5 to 200 nM.
The solutions were incubated for 3 h at 37 C before centrifugation.
100 mL of the supernatant was transferred to a 96 well-plate. The
absorbance of the supernatant at 565 nm was recorded with a
microplate reader (BioTek Instruments Inc.). Experiments were
carried out in triplicate. The haemolysis of RBC (%) was calculated as
((absorbance of sample e absorbance of negative control)/(absor-
bance of positive control-absorbance of negative control)) x 100
[57,58].
2.7. Ex vivo imaging
An aqueous solution of the QDs in PBS was injected subcutane-
ously into the left paw of rats at 30 pmol/g of body weight, corre-
sponding to a dose of 7.5mg/kg bodyweight. Ratswere killed 10min
post-injection, andan incisionwasmade to expose the axillary lymph
node (ALN) and thoracic lymph node (TLN) for ex vivo imaging. The
axillary area was illuminated with a collimated light-emitting diode
(LED) lamp (Thorlabs Inc. model M455L2) with peak emission at
455 nm and an incident power density on the sample of 3 mW/cm2.
Photoluminescence was imaged using a Peltier-cooled 12 bit single
chip 680  480 pixel charge-coupled device (CCD) colour camera
(Sensicam, PCO, Germany) incorporating a red/green/blue (RGB)
mosaic ﬁlter. The images were captured by a frame-grabber and
images were analysed using ImageJ.
Fig. 1. (A and B) TEM image (scale bar corresponds to 5 nm) and size distribution of bio CFQD® nanoparticles from TEM, (C) hydrodynamic size of surface-treated bio CFQD®
nanoparticles using DLS, (D) Photoluminescence emission spectrum of an aqueous solution of water soluble bio CFQD® nanoparticles (1 mM) using excitation at 405 nm.
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of experiments. Ratswere again administeredwith QDs at 30 pmol/g
of body weight, and the animals were sacriﬁced at various times
post-injection. The ALN and TLN were removed, tissues were placed
adjacently on anodised aluminium plates and were illuminatedwith
a collimated LED lamp at 455 nm. Ratswhich received only PBSwere
used as controls. Photoluminescence images of the QDs in excised
tissue specimens were recorded using a 16 bit Peltier-cooled
512  512 pixel charge-coupled device (CCD) camera (PIXIS 512F,
Princeton Instruments Inc.) equipped with a short-working distance
lens. Photoluminescence was recorded via a bandpass ﬁlter centred
at 620 nm (620DF40, Omega Optical Inc.). The systemwas controlled
by a PC computer using WinSpec software (Princeton Instruments
Inc.), which processed the 16 bit images.2.8. Microscopic localisation studies
Rats were administered with 30 pmol/g of body weight of the
QDs, as described in the previous section. Animals were killed 5min,
1 h, 4 h, 48 h, 5 days and 10 days post-injection and the axillary and
thoracic lymph nodeswere harvested formicroscopic imaging of QD
photoluminescence. The harvested tissues were ﬁrst frozen by
contact with an isopentane slush and stored at 80 C prior to use.
Five consecutive 10 mm thick tissue sections from tissue block
mounted with OCT Embedding Medium (Raymond A. Lamb, UK)
were cut from each sample and placed on clean glass slides. Pho-
toluminescence from the cryosections was recorded using an
inverted epiﬂuorescence microscope (Olympus IMT-2) equipped
with a 16 bit Peltier cooled 512  512 pixel CCD camera (Princeton
Instruments, model PIXIS 512 F). QD excitation was provided by a
405 nm laser diode module (Laser Components UK, Ltd). The ﬁlter
set for the phosphorescence imaging consisted of a 500 nm cut-on
dichroic mirror (Omega Optical Inc. 500 AGSP), and a long pass ﬁl-
ter (Schott RG570) together with a 40 nm bandpass emission ﬁlter
centred at 620 nm close to the peak emission of the QDs (Omega
Optical Inc., 620DF40). After recording the images, selected slides
were stained with haematoxylin and eosin (H & E) to identifymicroscopic localisation of QDs, and imaged with a NanoZoomer
digital slide scanner (Hamamatsu Inc.). An area from the stained
sectionwas then recorded at the same tissue site identiﬁed from the
corresponding stored photoluminescence image.
2.9. Biodistribution and pharmacokinetic studies
Nine groups of animals each composed of 3 rats were used for
the pharmacokinetic studies. One group served as the control
group and rats were injected subcutaneously into the paw with
100 mL of PBS. The other 8 groups were injected with 100 mL of QD
solution at a concentration of 30 pmol/g of body weight. The rats
were sacriﬁced at 1 h, 4 h, 24 h, 72 h, 10 days, 30 days, 60 days and
90 days and blood and various organs were collected for the
pharmacokinetic study.
2.10. Quantiﬁcation of uptake in organs
Various organs (the axillary lymph node, thoracic lymph node,
brain, thymus, lung, heart, liver, spleen, kidneys, colon, injection
site and blood) were collected, weighed and stored in a 80 C
freezer prior to use. For the quantiﬁcation of QDs in organs, 0.1 g of
each tissue in triplicate was prepared and digested by the addition
of 1 mL 70% nitric acid (HNO3). Samples were incubated with 70%
nitric acid overnight. The next day the samples were heated in a
water bath at 90 C for 4 h. Later, the samples were cooled at room
temperature and re-diluted by adding 5 mL distilled deionised
water. Afterwards, the samples were ﬁltered using 0.45 mm pore
poly (vinylidene ﬂuoride) membrane syringe ﬁlters. The indium
(In) ion content was quantiﬁed with inductively coupled plasma-
mass spectroscopy (ICP-MS) (PerkinElmer SCIEX ICP mass spec-
trometer, ELAN DRC 6100, USA) to determine the total indium in
the organs. For all ICP-MS measurements, nitric acid blank, blank
tissue samples, spiked samples with known QDs for calibration and
indium standards were prepared and tested concurrently with test
samples [59]. The tissues from the control rats without QD
administration were dissolved in a similar manner.
Fig. 2. In vitro viability of MCF-7 cells as a function of QDs concentration using the MTT
assay. Cells were incubated with bio CFQD® nanoparticles for 24 and 48 h. Data are
presented as mean ± standard deviation normalised to untreated control cells. Error
bars represent the standard deviation of triplicate experiments.
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solution
To investigate the stability of the quantum dots under in vivo
conditions, photoluminescence lifetime of QDs in aqueous solution
and the harvested axillary and thoracic lymphnodesweremeasured
using the ﬂuorescence lifetime imaging technique (FLIM). Animals
were injected using the same protocol as in the biodistribution
studies. Freshly excised lymph node samples, including controls
without QD, were placed in a small Petri dish incorporating a thin
glass coverslip bottom (Fluorodish, World Precision Inst. Ltd.) which
was placed on the stage of an inverted microscope (model TCS SP2,
Leica Microsystems Ltd.). A 63 water immersion objective was
used to image the samples which were excited with a pulsed
picosecond diode laser emitting at 470 nm at 1 MHz repetition rate
(Hamamatsu Photonics KK, Japan, model PLP-10, 90 ps pulse dura-
tion). Lifetime mapping was measured using a Time-Correlated
Single Photon Counting (TCSPC) FLIM system (Becker and Hickl
GmbH, Germany, model SPC150). Photoluminescence of QDs was
collected via a bandpass ﬁlter centred at 620 nm (620DF40, Omega
Optical Inc.). The 512  512 pixel images were analysed using SPC
Image software (Becker & Hickl GmbH, Germany).
3. Results and discussion
3.1. Cellular toxicity
The biocompatibility of the QDs was evaluated using a standard
viability assay and a haemolysis assay. Fig. 2 shows that after 24 h of
incubation with bio CFQD® nanoparticles negligible changes were
recorded vs. untreated control cells. In the case of prolonged
exposure (48 h) no signiﬁcant reduction in cell viability was
detected for QD-treated cells at concentrations as high as 200 nM
conﬁrming the good biocompatibility of bio CFQD® nanoparticles.
Similar results were obtained using SKOV-3 cells (human ovarian
cancer cells) incubated with bio CFQD® nanoparticles (data not
shown). The data presented here with bio CFQD® nanoparticles
compares favourably with other studies using cadmium-free QDs
[41,48,60]. It should be noted that lower toxicity may also arise
from the surface coating as well as the core/shell composition of the
QDs, so it is difﬁcult to discern the relative contributions of these
and other factors [61]. However, Brunetti et al. compared the
toxicity of InP/ZnS and CdSe/ZnS QDs in each case capped with
mercaptopropionic acid towards A459 human lung carcinoma cells
and other cell lines and concluded that leaching of cadmium ions
was the main factor responsible for the signiﬁcantly higher toxicity
of the cadmium-containing QDs [48].
3.2. Haemolysis test
Haemolytic properties are commonly used as a realiable tech-
nique to test the biocompatibility of nanoparticles under in vitro
conditions [57,58]. In this study, the biocompatibility of bio CFQD®
nanoparticles was carried out by investigating the extent of hae-
molysis over a broad concentration range (12.5e200 nM) following
incubation for 3 h. The bio CFQD® nanoparticles induced negligible
haemolysis over this concentration range with only 2.6 ± 0.1%
discernible (vs. the positive control at 100%) at the highest
concentrated of 200 nM. These results are consistent with the data
of Helle et al. who also reported negligible haemolysis of mouse
blood with cadmium-free QDs, whereas in the same study
cadmium-containing CdTeSe/ZnS QDs induced 80e90% haemolysis
after exposure for 2 h at 200 nM [41]. Overall, these ﬁndings clearly
indicate that the bio CFQD® nanoparticles possess good blood
biocompatibility.3.3. Ex vivo macroscopic and microscopic imaging
Macroscopic imaging of QD photoluminescence was carried out
on excised lymph nodes. An aqueous solution of the QDs was
injected subcutaneously into the left paw of rats and animals were
sacriﬁced 10 min post-injection. The axillary area was exposed,
illuminated with a 455 nm light emitting diode (LED), and images
were acquired using a CCD camera with 0.1 s integration time.
Owing to the high quantum yields and absorbance, the photo-
luminescence of the QDs in two regional lymph nodes corre-
sponding to left axillary lymph node (LALN) and left thoracic lymph
node (LTLN) was readily visible to the naked eye just after injection.
As shown in Fig. 3, the QD photoluminescence signal (red colour in
Fig. 3B) in the LALN and LTLN was easily detected by 10 min after
injection of the QDs similarly to what has been previously reported
with other type of QDs [ [33,34,41,45,62]). Residual green emission
in Fig. 3B is endogenous ﬂuorescence from tissues. These results
indicate that following subcutaneous injection, QDs entered the
lymphatics and migrated within minutes to the axillary and
thoracic lymph nodes. No signal speciﬁc to the LNs was detected in
control rats injected with PBS.
For the ex vivo photoluminescence images, the axillary and
thoracic lymph nodes were removed. The harvested tissues were
illuminated with a 455 nm LED lamp and images were acquired
using a CCD camera. Fig. 4 shows the ex vivo photoluminescence
images of ALN and TLN at 4 h, 48 h and 5 days post-injection. Bright
photoluminescence signal of QDs was detected from ALN and TLN
at each of the imaging time points. There was negligible photo-
luminescence signal in the lymph nodes of rats injected with PBS
(data not shown).
Cryosection microscopy of the harvested lymph nodes further
conﬁrmed the uptake of the QDs in ALN and TLN. Tissue sections
were imaged with a ﬂuorescence microscope. Fig. 5 shows a series
of cryosections from ALN and TLN in control and QD-injected rats at
various times post-injection, imaged quantitatively using the same
detection sensitivity. Compared to the control rats, QD-
administered rats exhibited a distinct photoluminescence signal
at all post-injection times up to 10 days in both axillary and thoracic
lymph nodes. On the same scale, specimens from control animals
showed negligible autoﬂuorescence. The images obtained show
that QDs remained photoluminescent for as long as 10 days. The
QDs must have remained relatively intact to retain detectable
photoluminescence signal over such a long period of time.
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an ALN at 5 min post-injection using 30 pmol/g, and then coun-
terstained using H&E. The results revealed that QDs were mainly
localised in the subcapsular sinuses and trabecular regions. The
subcapsular sinus is the most likely location of a metastatic carci-
noma in a lymph node. These ﬁndings are in agreement with other
studies where analyses of the resected tissues showed that QDs
were conﬁned to the outermost rim of the lymph node [34,63].Fig. 4. Ex vivo imaging of freshly harvested axillary and thoracic lymph nodes
following subcutaneous administration of QDs at 30 pmol/g, at 4 h, 48 h and 5 days
post-injection. The axillary lymph node (ALN) and thoracic lymph node (TLN) were
illuminated with a 455 nm LED lamp for 0.1 s and images were obtained using a CCD
camera. A: 4 h post-injection; B: 48 h post-injection; C: 5 days post-injection. False
colour bar scale with blue corresponding to lower intensity.3.4. In vivo biodistribution
It is important to understand the pharmacokinetic of QDs before
their translation into clinical use. In our study ICP-MS was used to
quantify the pharmacokinetics bymeasuring the indium (In) content
in selected organs and serum. A dose of 30 pmol/g was injected
subcutaneously into the paw of rats; tissue samples were taken at
1 h, 4 h, 24 h, 72 h, 10 days, 30 days, 60 days and 90 days after QD
administration. The concentration of indium in digested tissues was
determined using ICP-MS. 1 hr post-injection the indium content in
the left axillary lymph node (LALN) and left thoracic lymph node
(LTLN) was found to be 86 mg In/g tissue and 63 mg In/g tissue
respectively (Fig. 7). The indium concentration in both lymph nodes
increased gradually and reached a peak at 24 h post-injection
(130 mg In/g tissue and 127 mg In/g tissue for LALN and LTLN
respectively). The increase in indium concentration in the lymph
nodes following the injection was consistent with the decrease of
indium at the injection site in the same time span as the QDs
migrated from the injection site through the lymphatic duct system
to regional lymph nodes. After 24 h the lymph node accumulation
decreased steadily over time. A two-fold decrease of indium was
observed 30 days after injection (54 mg In/g tissue and 51 mg In/g
tissue for LALN and LTLN respectively). At 90 days post-injection only
a small amount of the indium remained in the LALN and LTLN (24 mg
In/g tissue and 19 mg In/g tissue respectively). Residual amounts
remained at the site of injection by 3 months post-injection.
It is interesting to note that the time-dependence data of the
indium content at the injection site, and lymph nodes are similar to
those of the Helle et al. study [41], using CuInS2/ZnS QDs encap-
sulated in PEG. In our study, QDs with PEG grafted to the surface are
also used whichmay explain the similar characteristics, although at
longer times owing to degradation the indium content may not
necessarily correspond to QD concentration.
Trace quantities of indiumwere detected in the liver (8.8 mg In/g
tissue) and spleen (6 mg In/g tissue) at 1 h post-injection (Fig. 8).
Afterwards, the concentration of the indium in both organs
increased slightly and reached the peak at 24 h (16 mg In/g tissue
and 12 mg In/g tissue for liver and spleen respectively), but this isFig. 3. (A) Colour and (B) photoluminescence image of retracted armpit area following QD
sacriﬁced 10 min post-injection. Tissues were illuminated with a collimated LED lamp with p
was recorded using a colour CCD camera. The green emission in (B) corresponds to tissue
lymph nodes.still an order of magnitude lower than levels found in the lymph
nodes. After 24 h the indium concentration in the liver and spleen
started to decrease over time. By 90 days, the quantity of indium in
the liver had reduced by more than 90% (16.6 mg In/g tissue vs.
1.51 mg In/g tissue, Fig. 8) suggesting hepatobiliary elimination was
taking place. Small quantities of indium were detected in kidney
which could be due to excretion of QDs from urinary tract in
addition to hepatobiliary pathway, but at the longer times the
detection of indium is more likely to be due to smaller breakdown
products. The hydrodynamic diameter of the QDs although rela-
tively small for water-soluble QDs is too large for efﬁcient urinary
excretion according to studies of Choi et al. [64].
Overall, the results show that subcutaneously injected QDs in
the paw mainly accumulated in the regional lymph nodes with
negligible accumulation in the liver and spleen thus decreasing the
likelihood of QD toxicity. As evident from Fig. 8 negligible quanti-
ties of indiumwere detected in all other tissues with no signiﬁcant
trend (thymus, lungs, heart, kidneys, colon). Trace quantities of
indium in serum samples at all-time points was also detected.administration. QDs were injected subcutaneously into the left paw and the rat was
eak emission at 455 nm (acquisition time: 0.1 s) and the QDs photoluminescence signal
autoﬂuorescence, and the red to the QDs photoluminescence in axillary and thoracic
Fig. 5. Photoluminescence microscopy images of cryosections taken from rat axillary (ALN), thoracic (TLN) lymph nodes and control images (G). Top row shows distribution of QDs
in axillary lymph node (ALN) and the bottom row displays QDs distribution in thoracic lymph node (TLN) at various time intervals post-injection: (A): 5 min, (B): 1 h, (C): 4 h, (D):
48 h, (E): 5 days and (F): 10 days. G: images from the control rats without QDs injection; image scale: 500  500 mm. False colour bar scale with blue corresponding to lower
intensity.
Fig. 6. Photoluminescence (A) image (250  250 mm) and corresponding H & E stained image (B) and lower power image (C) of same ﬁeld from a cryosection of rat axillary lymph
node 5 min after QDs injection. High intensities are evident in the subcapsular sinuses (at the top) and trabecular regions (at the left) as shown by the arrows.
Fig. 7. Quantitative analysis of biodistribution of QDs in rats using ICP-MS. Rats were injected subcutaneously at a concentration of 30 pmol/g of body weight. The indium content in
left axillary lymph node (LALN), left thoracic lymph node (LTLN) and injection sites were quantiﬁed using ICP-MS and were expressed as the quantity of indium (in mg) per gram of
tissue. Data are mean ± SD (n ¼ 3 per group).
E. Yaghini et al. / Biomaterials 104 (2016) 182e191188
Fig. 8. Biodistribution of QDs in various tissues and serum in rats as a function of post-injection time. Rats were injected subcutaneously with QDs at a concentration of 30 pmol/g
body weight. The indium content in organs and serum was quantiﬁed using ICP-MS using ICP-MS and were expressed as the quantity of indium (in mg) per gram of tissue or per
millilitre of blood. Data are mean ± SD (n ¼ 3 per group).
E. Yaghini et al. / Biomaterials 104 (2016) 182e191 1893.5. Ex vivo ﬂuorescence lifetime imaging (FLIM)
To investigate whether uptake into tissue perturbed the pho-
tophysical properties of the QDs, we measured the photo-
luminescence lifetime in ex vivo axillary and thoracic lymph nodes
using the ﬂuorescence lifetime imaging technique (FLIM) incor-
porating time-correlated single photon counting (TCSPC) [65,66].
For these measurements, a diode laser with a variable repetition
rate was used to enable the adjustment of the time window to
collect the entire decay before re-exciting the sample [67].
QDs were injected subcutaneously into the paw of rats, as
described previously for the ex vivo imaging studies. Animals were
sacriﬁced 10 min post-injection and the LALN and LTLN were
removed for the imaging measurements. Excitation of the QDs was
carried out using a picosecond laser diode at 470 nm. Fig. 9 shows a
lifetime image of a rat thoracic lymph node and mean lifetime
histogram. The area images correspond to the subcapsular sinuses
and trabecular regions where there is high accumulation of the QDs
as shown in Fig. 6.Fig. 9. FLIM image (A) of a rat thoracic lymph node (238  238 mm) and (B) mean lifetim
injection of QDs at 30 pmol/g of body weight.Biexponential decay analysis of the time-resolved QD photo-
luminescence intensity (It) was carried out using the equation,
It ¼ A1exp (t/t1) þ A2exp (et/t2) þ B, where A and t are the
fractional amplitude and lifetime, and B is the background; in view
of the FLIM photon statistics, the use of more complex decay
models in a single pixel is not statistically justiﬁed.
Biexponential ﬁtting of the whole-ﬁeld LALN data gave a major
short lifetime component of t1¼23 ns with a large pre-exponential
factor or amplitude of 0.87, and a long lifetime component of
t2 ¼ 142 ns with lower amplitude (Table 1). For the LTLN, the major
short and long lifetimes were 20 and 120 ns respectively. The
amplitude weighted mean lifetimes for the LALN and LTLN are 39
and 35 ns respectively [68]. These values are close to the amplitude
weighted mean lifetime of the QDs measured in aqueous solution
(0.01 M PBS, pH 7.4) at 41 ns. The similarity in the emission life-
times suggests that no signiﬁcant photoluminescence quenching
occurs for the QDs when present in the lymph nodes, although the
value observed for the thoracic sample is about 10% lower than for
the QD solution. As far as we are aware this is the ﬁrst study toe histogram with false colour scale in ns. Images were taken following subcutaneous
Table 1
Photoluminescence lifetime components of QDs in axillary and thoracic lymph
nodes compared to aqueous solution (100 nM).
QDs photoluminescence lifetime t/ns and fractional
amplitudes (A)
t1 (A1) t2 (A2)
Aqueous solution 26
(0.85)
132
(0.15)
Axillary lymph node 23
(0.87)
142
(0.13)
Thoracic lymph node 20
(0.85)
120
(0.15)
E. Yaghini et al. / Biomaterials 104 (2016) 182e191190produce such comparison. The relatively long photoluminescence
lifetime of QDs could also provide a means to distinguish the QDs
photoluminescence from shorter-lived autoﬂuorescence using
time-gated imaging.
4. Conclusions
QD nanoparticles have several unique properties which are
potentially useful for clinical applications such as intraoperative
SLN mapping. However, most of the engineered core/shell QDs
contain regulated heavy metals which would severely restrict their
clinical use. Therefore, in the present study we have investigated
new cadmium-free QDs (bio CFQD® nanoparticles) which can be
prepared in bulk with high photoluminescence quantum yields.
These quantum dots are surface functionalised with a biocompat-
ible coating to confer water solubility. We examined their potential
for in vivo SLNmapping using a regional lymph node animal model.
These bright and photostable indium-based QDs are soluble and
colloidally stable in water. Using photoluminescence imaging we
showed that the bio CFQD® nanoparticles, when injected subcu-
taneously into paw of rats, accumulated preferentially in two
regional LNs draining the thoracic mammary fat pads in rats. The
biodistribution study using chemical extraction revealed that with
subcutaneous injection of QDs into the paw, retention is strongly
conﬁned to regional lymph nodes since only trace quantities of QDs
were detected in other organs. Localisation took place within mi-
nutes of injection and photoluminescence was stable for an
extended period unlike blue dyes which drain relatively quickly
from lymph nodes. This observation could be advantageous since
false positive samples related to the fast migration of the dyes
across the lymphatic channel can be avoided and the extended
retention is logistically easier to deal with in a clinical setting.
Furthermore the engineered bio CFQD® nanoparticles do not
contain any Class A elements (Cd, Pb and Hg) therefore their low
intrinsic toxicity may further promote their biomedical applica-
tions. However additional work will be needed to study long-term
toxicity effects of bio CFQD® nanoparticles.
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